PHATHOM PHARMACEUTICALS INC's ticker is PHAT and the CUSIP is 71722W107. A total of 85 filers reported holding PHATHOM PHARMACEUTICALS INC in Q3 2021. The put-call ratio across all filers is - and the average weighting 0.6%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2021 | $14,057,000 | +3.7% | 415,277 | +15.1% | 0.95% | -91.2% |
| Q1 2021 | $13,557,000 | +13.1% | 360,939 | 0.0% | 10.78% | -30.7% |
| Q4 2020 | $11,990,000 | +41.7% | 360,939 | +56.4% | 15.57% | +18.3% |
| Q3 2020 | $8,461,000 | -32.5% | 230,727 | -39.5% | 13.17% | +71.1% |
| Q2 2020 | $12,541,000 | +34.6% | 381,069 | +5.6% | 7.70% | +99.4% |
| Q1 2020 | $9,319,000 | -17.1% | 360,939 | 0.0% | 3.86% | +30.2% |
| Q4 2019 | $11,240,000 | – | 360,939 | – | 2.96% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Medicxi Ventures Management (Jersey) Ltd | 3,760,869 | $39,000,212 | 12.45% |
| Frazier Life Sciences Management, L.P. | 10,109,279 | $104,833,223 | 6.96% |
| Decheng Capital Management III (Cayman), LLC | 850,000 | $8,814,500 | 2.94% |
| Carlyle Group Inc. | 3,496,808 | $36,191,963 | 1.57% |
| Ghost Tree Capital, LLC | 395,000 | $4,096,150 | 1.35% |
| Newtyn Management, LLC | 500,000 | $5,185,000 | 1.28% |
| Altium Capital Management LP | 220,000 | $2,281,400 | 1.19% |
| StepStone Group LP | 422,085 | $4,377,021 | 0.98% |
| MPM BioImpact LLC | 347,332 | $3,601,833 | 0.96% |
| NEA Management Company, LLC | 1,276,595 | $12,238,290 | 0.94% |